Dimeric IgA specifically disables intracellular mutated oncodrivers

: Prince Stuart, Hollmén Maija

: 2023

: Immunity

: 56

: 11

: 2461

: 2463

: 1074-7613

: 1097-4180

DOI: https://doi.org/10.1016/j.immuni.2023.10.014

: https://doi.org/10.1016/j.immuni.2023.10.014

A prevailing belief in the immunotherapy field has been that antibody therapy can effectively target only extracellular antigens. In this issue of Immunity, Biswas et al. demonstrate therapeutically effective targeting, neutralization, and removal of mutated oncodriver proteins from within epithelial cancer cells by treatment with pIgR-dependent, transcytosing dimeric-IgA antibodies.